- $122.83m
- $98.88m
- CNY650.71m
- 41
- 41
- 87
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.62 | ||
| Price to Tang. Book | 1.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.36 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -119.91% | ||
| Return on Equity | -92.3% | ||
| Operating Margin | -107.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 225.18 | 323.43 | 424.49 | 531.95 | 650.71 | 723.59 | 895.51 | 45.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genetron Holdings Limited is a precision oncology company that specializes in cancer molecular profiling and harnesses technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. The Company operates its businesses primarily within the China market.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- April 1st, 2018
- Public Since
- June 19th, 2020
- No. of Employees
- 799
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 457,743,530
- Address
- 1-2/F, Building 11, Beijing, 102206
- Web
- https://www.genetronhealth.com
- Phone
- +86 1050907500
- Auditors
- PricewaterhouseCoopers Zhong Tian LLP
Upcoming Events for GTH
Similar to GTH
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
As of Today at 19:09 UTC, shares in Genetron Holdings are trading at $4.03. This share price information is delayed by 15 minutes.
Shares in Genetron Holdings last closed at $4.03 and the price had moved by +31.54% over the past 365 days. In terms of relative price strength the Genetron Holdings share price has outperformed the S&P500 Index by +2.87% over the past year.
The overall consensus recommendation for Genetron Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Genetron Holdings does not currently pay a dividend.
Genetron Holdings does not currently pay a dividend.
Genetron Holdings does not currently pay a dividend.
To buy shares in Genetron Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $4.03, shares in Genetron Holdings had a market capitalisation of $122.83m.
Here are the trading details for Genetron Holdings:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: GTH
Based on an overall assessment of its quality, value and momentum Genetron Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Genetron Holdings is $1.33. That is 66.97% below the last closing price of $4.03.
Analysts covering Genetron Holdings currently have a consensus Earnings Per Share (EPS) forecast of -CNY1.10 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genetron Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +34.84%.
As of the last closing price of $4.03, shares in Genetron Holdings were trading +21.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genetron Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Genetron Holdings' directors